A 5-year-old intact male Doberman Pinscher presents with ...

Thank you for reaching out regarding this Doberman Pinscher. The clinical presentation of progressive exercise intolerance and syncope, coupled with severe left ventricular dilation (FS 15%) and frequent VPCs, strongly indicates symptomatic dilated cardiomyopathy (DCM). This patient is definitively in Stage C of DCM.

For a Doberman Pinscher diagnosed with DCM, pimobendan is a cornerstone therapy and its initiation is clearly indicated in this scenario.

Here are the current guidelines for initiating pimobendan in Dobermans with DCM:

Occult DCM (Stage B2): The PROTECT study demonstrated that initiating pimobendan in Dobermans with occult DCM (i.e., structural heart disease and/or significant ventricular arrhythmias without overt clinical signs of heart failure) significantly delays the onset of congestive heart failure (CHF) and improves survival time. Therefore, even if this Doberman were asymptomatic, pimobendan would be indicated given the echocardiographic changes (FS 15% is well below the normal range, indicating significant systolic dysfunction).

Symptomatic DCM (Stage C): In a Doberman presenting with clinical signs such as exercise intolerance and syncope, as your patient is, pimobendan is absolutely indicated. Its positive inotropic and vasodilatory effects are crucial for improving cardiac output, reducing myocardial workload, and alleviating clinical signs associated with systolic dysfunction. It is a key component of multi-drug therapy for improving quality of life and prolonging survival in dogs with symptomatic DCM.

Pimobendan Dosing and Considerations:

* Dose: Based on the VERIFIED DRUG FORMULARY, the recommended dose for dogs is 0.25-0.3 mg/kg PO Every 12 hours.
* Administration: It is crucial to administer pimobendan on an empty stomach, approximately one hour before food, as food can significantly reduce its absorption (by about 30%).
* Contraindications: While contraindicated in conditions like hypertrophic cardiomyopathy where dynamic outflow tract obstruction may exist, it is the primary inotropic support for DCM.

Comprehensive Management for this Patient:

Beyond pimobendan, given the severe systolic dysfunction and clinical signs, a comprehensive approach is warranted:

* ACE Inhibitor: An ACE inhibitor such as enalapril or benazepril should be initiated to counteract the activation of the Renin-Angiotensin-Aldosterone System (RAAS). For enalapril, the dose is 0.5 mg/kg PO Every 12-24 hours. Monitor renal values and blood pressure 5-7 days after starting.
* Furosemide: While the primary signs are exercise intolerance and syncope (indicating low cardiac output), pulmonary edema may also be present or impending. If there are any signs of CHF (tachypnea, crackles, radiographic evidence of pulmonary edema), furosemide should be added. The chronic dose for dogs is 1-4 mg/kg PO Every 12 hours, titrated to the lowest effective dose based on the patient's respiratory rate at home.
* Antiarrhythmics: The frequent VPCs and syncope are highly concerning. A 24-hour Holter monitor would be invaluable to quantify the arrhythmia burden and characterize its morphology (e.g., origin from RV in Dobermans). Given the syncope, antiarrhythmic therapy, typically with sotalol (1-3 mg/kg PO Every 12 hours), is strongly indicated. Start at 2 mg/kg q12h and monitor with ECG.
* Monitoring: Closely monitor renal values, electrolytes, and blood pressure during initiation and adjustment of these medications. Educate the owner to monitor sleeping respiratory rate at home (<30 breaths/minute is normal) as an early indicator of impending CHF.

This Doberman's condition is serious, and prompt, aggressive medical management with pimobendan as a core component, alongside other indicated therapies, is essential to stabilize the patient and improve their prognosis. I would recommend referral for a full cardiology workup if not already performed, especially for comprehensive arrhythmia management and to rule out any other contributing factors.